NDAORALTABLET
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
BRENZAVVY (bexagliflozin) by TheracosBio is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2023.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRENZAVVY (bexagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor approved in January 2023 for the treatment of type 2 diabetes. It works by inhibiting renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering blood glucose levels. The drug is currently in peak commercial lifecycle stage.
Peak14.9 years to LOE
Recent approval positions BRENZAVVY in growth phase with commercial potential, though team size and market penetration data remain limited in current market data.
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BRENZAVVY offers career opportunities in a growing but competitive diabetes market segment; roles will focus primarily on market penetration, payer negotiation, and field execution given recent approval status. Career growth trajectory is dependent on market adoption rates and competitive differentiation success against entrenched SGLT2i players.
Brand Manager
Worked on BRENZAVVY at TheracosBio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.